AstraZeneca Vax – Sputnik V Combination Study

Trial Identifier: D8111C00003
Sponsor: AstraZeneca
Collaborator:
R-Pharm
The Russian Direct Investment Fund (RDIF)
The Gamaleya National Center of Epidemiology & Microbiology
NCTID:: NCT04684446
Start Date: August 2021
Primary Completion Date: April 2022
Condition: COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Belarus Vitebsk, Belarus, 210037
Russian Federation Moscow, Russian Federation, 115419
Russian Federation Moscow, Russian Federation, 109240
Russian Federation Moscow, Russian Federation, 121359
Russian Federation Saint-Petersburg, Russian Federation, 197376
Russian Federation Saint-Petersburg, Russian Federation, 196158
Russian Federation St. Petersburg, Russian Federation, 197022